Topical tacrolimus, genital lichen sclerosus, and risk of squamous cell carcinoma

Archives of Dermatology

Volumn 140, Issue 9, 2004, Pages 1169-

  Bunker, C B ^a   Neill, S ^a   Staughton, R C D ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE; IMMUNOSUPPRESSIVE AGENT; STEROID; TACROLIMUS;

CANCER DIAGNOSIS; CANCER RISK; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LICHEN SCLEROSUS ET ATROPHICUS; NOTE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 4544343676     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.9.1169-a     Document Type: Note

References (7)

1. Bohm M, Frieling U, Luger TA, Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139:922-924.
2. Kunstfeld R, Kirnbauer R, Stingl G, Karlhofer FM. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol. 2003;139:850-852.
3. Assmann T, Becker-Wegerich P, Grewe M, Megahed M, Ruzicka T. Tacrolimus ointment for the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2003;48:935-937.
4. Pandher BS, Rustin MH, Kaisary AV. Treatment of balanitis xerotica obliterans with topical tacrolimus. J Urol. 2003;170:923.
5. Neill SM, Ridley CM. Management of anogenital lichen sclerosus. Clin Exp Dermatol. 2001;26:637-643.
6. Bunker CB. Topics in penile dermatology. Clin Exp Dermatol. 2001;26:469-479.
7. Neill SM, Tatnall FM, Cox NH; British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br J Dermatol. 2002;147:640-649.